Biobot Surgical, an innovator in robotic-assisted prostate disease management, is proud to announce that the Mona Lisa 2.0 has received CE Certification, adding to the US FDA, Australia TGA and Singapore HSA approvals. This milestone paves the way for Mona Lisa 2.0 to be utilized in clinical settings across an additional 32 countries, bringing its revolutionary features to urologists and their patients.
Mona Lisa 2.0 delivers cutting-edge precision, efficiency, and versatility to enhance prostate care. The following key features of the new robot empower urologists to deliver superior outcomes:
1. Advanced Positioning for Prostate Interventional Procedures
The Mona Lisa 2.0 supports precise targeting and flexibility in prostate biopsies and ablations. With the ability to adjust the prostate model and planned needle locations in real time, it accounts for shifts during the procedure, supporting precision in both diagnostic and therapeutic interventions, and ensuring accurate treatments even in dynamic clinical scenarios.
2. Enhanced Needle Accuracy with Needle Deflection Adjustment
A new software capability allows urologists to adjust needle trajectory deviations caused by tissue heterogeneity or needle tip design, ensuring precise alignment with the planned target. This increased accuracy leads to more reliable biopsies and treatments, improving diagnostic confidence and reducing risks.
3. Streamlined Multi-needle Insertions and Optimized Visualization
Multi-needle Insertion optimizes efficiency during complex interventions, reducing manual effort and enhancing workflow precision. The visual overlays of lesion margin and simulated ablation zone help with targeting of the region of interest while avoiding critical structures.
A Game-Changer for European Urologists
“The CE Certification of Mona Lisa 2.0 is a significant milestone for Biobot Surgical,” said Albert Lee, CEO of Biobot Surgical. “With its advanced capabilities, Mona Lisa 2.0 is set to redefine prostate care across Europe. Urologists can now leverage its unmatched precision and adaptability to deliver superior patient outcomes.”
The Mona Lisa 2.0 combines precision, efficiency, and adaptability to set a new standard in robotic-assisted prostate care. Building on 25,000 cases performed globally on the Mona Lisa Platform (including in the US), this cutting-edge platform is poised to revolutionize urology practices in Europe, ensuring better care for patients and greater efficiency for healthcare providers.
